Drug intelligence / Profile preview

technetium (99mTc) ethylenedicysteine

Development stage
Unknown
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
Administration
Intravenous
01

Overview

Technetium (99mTc) ethylenedicysteine (99mTc-EC) is a diagnostic radiopharmaceutical used in dynamic renal scintigraphy (diuretic renography) to evaluate renal function, particularly renal tubular function and urinary tract drainage. It was developed as an alternative to technetium-99m mercaptoacetyltriglycine (99mTc-MAG3) and iodine-131 orthoiodohippurate (131I-OIH). 99mTc-EC is cleared rapidly from the blood and excreted almost exclusively by the kidneys via active tubular secretion mediated by organic anion transporters (OAT1 and OAT3). It provides high-quality scintigraphic images of the kidneys with low background activity and negligible hepatobiliary excretion, making it highly effective for diagnosing urinary tract obstruction, assessing split renal function, and evaluating renal transplants, even in patients with impaired renal function.

Other names
99mTc-EC99mTc-L,L-EC99mTc-ethylenedicysteineTc-99m-ECTc99m-ECTc 99m-ECtechnetium (99mTc)-L,L-ethylenedicysteinetechnetium Tc 99m ethylenedicysteinetechnetium Tc 99m-ethylenedicysteine
02

Targets

OAT1 (Organic anion transporter 1)SLC22A8 (Organic anion transporter 3)

Beyond the preview

Go deeper on technetium (99mTc) ethylenedicysteine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on technetium (99mTc) ethylenedicysteine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call